OncoMatch/Clinical Trials/NCT06394128
Cangpo Liujun Prescription on Cancer-related Fatigue in Advanced Colorectal Cancer With Spleen Deficiency and Dampness Excess
Is NCT06394128 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cangpo Liujun Prescription for cancer-related fatigue.
Treatment: Cangpo Liujun Prescription — The goal of this clinical trial is to learn if Cangpo Liujun Prescription works to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy with spleen deficiency and dampness excess. It will also learn about the safety of Cangpo Liujun Prescription. The main questions it aims to answer are: Does Cangpo Liujun Prescription improve the fatigue symptoms for participants? How about the relationship between taking Cangpo Liujun Prescription and distribution of intestinal flora? Researchers will compare Cangpo Liujun Prescription to a placebo (a look-alike substance that contains no drug) to see if Cangpo Liujun decoction works to treat cancer-related fatigue in patients with advanced colorectal cancer undergoing second-line chemotherapy with spleen deficiency and dampness excess. Participants will: Take Cangpo Liujun Prescription or a placebo every day for 3 months Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms Take blood samples to detect immune function and inflammatory factors Collected Feces for gut microbiota analysis
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
No combined hematopoietic system diseases, such as anemia, requiring anemia correction drugs
Kidney function
serum creatinine < 1.5 times ULN
Liver function
ALT or AST < 5 times ULN; Bilirubin < 1.5 times ULN
Cardiac function
No heart failure or serious and difficult to control organic lesions
Patients with severe liver and kidney dysfunction (serum creatinine 1.5 times ULN; ALT or AST5 times ULN; Bilirubin 1.5 times ULN); Combined with hematopoietic system diseases, such as anemia, requiring anemia correction drugs; heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify